NCT05876364 is a Phase 1 clinical trial of QTP104 1ug in COVID-19, sponsored by Quratis Inc..

Who is sponsoring NCT05876364?

NCT05876364 is sponsored by Quratis Inc..

What drugs are being tested in NCT05876364?

Interventions in NCT05876364: QTP104 1ug, QTP104 5ug, QTP104 25ug.

What condition does NCT05876364 study?

NCT05876364 studies COVID-19, SARS-CoV-2.

Is NCT05876364 still recruiting?

NCT05876364 is currently status unknown. Last updated 25 May 2023.

Last reviewed 2023-05-25 · How we verify

NCT05876364

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study to Assess Safety, Reactogenicity and Immunogenicity of the repRNA(QTP104) Vaccine Against SARS-CoV-2(COVID-19)

Status unknown Phase 1 Last updated 25 May 2023

What this trial tests

Phase 1 trial testing QTP104 1ug in COVID-19 in 36 participants. Status unknown.

Timeline

19 November 2021

Primary endpoint
13 June 2022

30 August 2023

Quick facts

Lead sponsor	Quratis Inc.
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	prevention
Enrollment	36
Start date	19 November 2021
Primary completion	13 June 2022
Estimated completion	30 August 2023
Sites	2 locations across South Korea

Drugs / interventions tested

QTP104 1ug — full drug profile →
QTP104 5ug — full drug profile →
QTP104 25ug — full drug profile →

Conditions studied

COVID-19 — all drugs for COVID-19 →
SARS-CoV-2 — all drugs for SARS-CoV-2 →

Sponsor

Quratis Inc. — full company profile →

Who can join

Adults 19 to 55, any sex, with COVID-19 or SARS-CoV-2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is to evaluate the safety, reactogenicity, and immunogenicity of the QTP104 vaccine against SARS-CoV-2 infection in healthy adults.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Nanotechnology's frontier in combatting infectious and inflammatory diseases: prevention and treatment.
Huang Y, Guo X, Wu Y, Chen X, et al · · 2024 · cited 188× · PMID 38378653 · DOI 10.1038/s41392-024-01745-z
The advent of clinical self-amplifying RNA vaccines.
Casmil IC, Jin J, Won EJ, Huang C, et al · · 2025 · cited 40× · PMID 40186353 · DOI 10.1016/j.ymthe.2025.03.060
Vaccine adjuvants for infectious disease in the clinic.
Goetz M, Thotathil N, Zhao Z, Mitragotri S. · · 2024 · cited 29× · PMID 39036089 · DOI 10.1002/btm2.10663
mRNA Vaccines Against COVID-19 as Trailblazers for Other Human Infectious Diseases.
Brandi R, Paganelli A, D'Amelio R, Giuliani P, et al · · 2024 · cited 10× · PMID 39772079 · DOI 10.3390/vaccines12121418
Brief Insights into mRNA Vaccines: Their Successful Production and Nanoformulation for Effective Response against COVID-19 and Their Potential Success for Influenza A and B.
Parveen A, Elkordy AA. · · 2024 · cited 9× · PMID 38921798 · DOI 10.3390/pathogens13060500
Replicon RNA vaccines: design, delivery, and immunogenicity in infectious diseases and cancer.
Tang L, Que H, Wei Y, Yang T, et al · · 2025 · cited 2× · PMID 40247301 · DOI 10.1186/s13045-025-01694-2

Verify or expand the search:

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05876364 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Quratis Inc.
Last refreshed: 25 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05876364.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing